Despite some public virtue signalling, the Canadian government is not doing all it can to improve global access to COVID-19 vaccines. Canada has yet to announce its position on the WTO patent waiver.
Rigor acadêmico, estilo jornalístico
Todos os artigos de Pharmaceutical industry
Exibindo 21 - 40 de 56 artigos
A vaccination queue-jumping scandal in Peru has caused a massive uproar in the South American country. It could also be a wake-up call for all nations.
‘Orphan drugs’ with high price points are being tested as treatments for COVID-19. There’s a better way to spur low-cost innovation for new drugs.
A private market should have no place in the rollout of a COVID vaccine.
The funding, procurement, storage and distribution of a vaccine present huge challenges to all governments, including New Zealand’s.
Patients have a stake in the relationship between doctors and pharmaceutical companies, so the CMA’s current review of its guidelines for doctor/pharma interactions is everybody’s business.
Medical innovation is often accelerated in a time of crisis.
Health Canada devotes far more resources to getting new drugs onto the market compared to making sure that drugs already being sold are safe.
The UK is investing heavily in preparation for mass manufacturing of a working COVID-19 vaccine.
Toilet paper shortages were bad enough. A shortage of drugs during the COVID-19 pandemic would be worse. A provision in the Canadian government’s relief package aims to prevent that from happening.
Drug shortages occur regularly in the US, even in the best of times. The pharmaceutical supply chain embodies ‘just in time’ shipping and has little built-in redundancy.
Too often, pharmaceutical companies and device manufacturers exert influence in how their products are tested in the research phase and recommended in the clinic.
The government should work with drug companies, not against them.
The first study to assess the carbon footprint of the pharmaceutical industry finds that it is far from green.
Two community pharmacists suggest a way for improving the palatability of evidence-based universal pharmacare – for those working in health insurance, pharmacy and the pharmaceutical industry.
Fixes for small pieces of massive problems show that overarching crises may be less hopeless than they appear.
These four “natural” therapies for depression have rigorous, peer-reviewed scientific studies to support their use.
Researchers who’ve created a kidney-on-a-chip explain why these kinds of devices are an improvement over traditional ways to test new drugs.
Pharmaceutical companies focus on small molecules they’ve devised – and can easily patent. But nature’s already come up with many antibacterial compounds that drug designers could use to make medicines.
Health Canada proposes to increase fees to the pharmaceutical industry for prescription drug approval. This will compromise drug safety and is a risk to the health of the Canadian public.
Principais colaboradores
-
Joel Lexchin é um amigo do The Conversation.Professor Emeritus of Health Policy and Management, York University, Canada
-
Professor, School of Pharmacy and Charles Perkins Centre, University of Sydney
-
Assistant Professor, Bond University
-
Professor, School of Population and Public Health, University of British Columbia
-
Lecturer in Criminology, University of Auckland, Waipapa Taumata Rau
-
Reader in Intellectual Property Law, City, University of London
-
Adjunct Professor, Australian Centre for Health Law Research, School of Law, Queensland University of Technology
-
Associate Professor: Medicinal plant biotechnology, Stellenbosch University
-
Professor and Distinguished Research Chair, Globalization and Health Equity, L’Université d’Ottawa/University of Ottawa
-
Assistant Professor, Sociology, University of Victoria
-
Research Fellow, Flinders University
-
Research fellow, Centre for Health Economics, University of York
-
Professor, Centre for Health Economics, University of York
-
Associate Professor of Chemistry, Northeastern University
-
Associate Professor in the SAMRC Centre for Health Economics and Decision Science - PRICELESS SA (Priority Cost Effective Lessons in Systems Strengthening South Africa), University of the Witwatersrand
